


Accepted Manuscript

Efficacy and Limitations of Budesonide as a Second-line Treatment for Patients With Autoimmune Hepatitis

M. Peiseler, T. Liebscher, M. Sebode, R. Zenouzi, J. Hartl, H. Ehlken, N. Pannicke, C. Weiler-Normann, A.W. Lohse, C. Schramm



PII: S1542-3565(17)30060-5
DOI: [10.1016/j.cgh.2016.12.040](https://doi.org/10.1016/j.cgh.2016.12.040)
Reference: YJCGH 55075

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 15 December 2016

Please cite this article as: Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse A, Schramm C, Efficacy and Limitations of Budesonide as a Second-line Treatment for Patients With Autoimmune Hepatitis, *Clinical Gastroenterology and Hepatology* (2017), doi: 10.1016/j.cgh.2016.12.040.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Efficacy and Limitations of Budesonide as a Second-line Treatment for Patients With Autoimmune Hepatitis

Peiseler M*, Liebscher T*, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse AW, Schramm C#.

I. Department of Medicine, University Medical Centre Hamburg-Eppendorf

* both authors contributed equally

Grant support: no financial support was given.

Abbreviations: AASLD, American Association of the Study of Liver Diseases; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ANA, anti-nuclear antibodies; AST, aspartate aminotransferase; BW, body weight; DXA, Dual-energy X-ray absorptiometry; EASL, European Association for the Study of the Liver; IgG, immunoglobulin G; LKM-1, liver kidney microsomal type-1 antibodies; MMF, mycophenolate mofetil; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SLA/LP, soluble liver antigen/liver pancreas antibodies; SLE, Systemic lupus erythematosus; SMA, smooth muscle antibodies; 6-MP, 6-mercaptopurine.

Corresponding author: Christoph Schramm. Address: University Medical Centre Hamburg-Eppendorf (UKE), Martinistrasse 52, 20246 Hamburg, Germany. Tel.: +49 407410 52545; Fax: +49 40 7410 40272. E-mail address: cschramm@uke.de (C. Schramm).

Disclosures: C.S. received lecture fees from Falk Foundation. A.W.L. received co-sponsorship of educational course by Falk Pharma. All others declare no conflict of interest.

Download English Version:

<https://daneshyari.com/en/article/8725214>

Download Persian Version:

<https://daneshyari.com/article/8725214>

[Daneshyari.com](https://daneshyari.com)